From 92272eca05f6171a35b198f3fa511cc70b68ddbb Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 15:54:13 +0000 Subject: [PATCH 1/2] extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...-cardiovascular-and-metabolic-endpoints.md | 6 ++++ ...ients-undermining-chronic-use-economics.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...mployer-cost-savings-cancer-reduction.json | 32 +++++++++++++++++++ ...-employer-cost-savings-cancer-reduction.md | 17 +++++++++- 5 files changed, 66 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 764c971a2..3f6aac7b5 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0 Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's 192K patient analysis adds cancer risk reduction to the multi-organ protection profile: ~50% lower ovarian cancer and 14% lower breast cancer in female users, plus associations with lower osteoporosis and rheumatoid arthritis rates. Adherent users (80%+) showed 47% MACE reduction for women and 26% for men, confirming cardiovascular benefits with sex-differential effects. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 3d9ef0bb0..b10ed217f 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -59,6 +59,12 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2 The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon data shows adherence is the binding variable for cost-effectiveness: benefits scale dramatically with 80%+ adherence, with diabetes patients showing 9 percentage points lower medical cost growth at 30 months (vs. 6 points for all users) and weight loss patients showing 7 points lower (vs. 3 points for all users). This quantifies the economic penalty of low persistence. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index b9259e3a0..4ab5daf79 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's commercial claims data (employer-sponsored insurance) shows strong benefits for adherent users, but the 192K sample represents healthier/wealthier employees with better coverage. The temporal cost pattern (costs up 23% year 1, then down to 2% growth year 2+) makes affordability barriers particularly damaging because patients who discontinue in year 1 bear costs without capturing savings. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json new file mode 100644 index 000000000..76f6ffaf4 --- /dev/null +++ b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 0caf70348..5824115c7 100644 --- a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,9 +7,13 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary. flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"] + + +## Key Facts +- Aon analyzed U.S. commercial health claims data from 192,000+ GLP-1 users in a multi-year study released January 13, 2026 +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users +- After 12 months: medical costs grow 2% vs. 6% for non-users +- For diabetes indication: medical cost growth 6 percentage points lower at 30 months; 9 points lower with 80%+ adherence +- For weight loss indication: cost growth 3 points lower at 18 months; 7 points lower with consistent use +- Female GLP-1 users: ~50% lower incidence of ovarian cancer +- Female GLP-1 users: 14% lower incidence of breast cancer +- Adherent users (80%+): 47% MACE reduction for women, 26% for men -- 2.45.2 From f920e3d5eb8a9c50eb4a81ea097e7737eccba10e Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 15:54:37 +0000 Subject: [PATCH 2/2] auto-fix: strip 3 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...alue-across-kidney-cardiovascular-and-metabolic-endpoints.md | 2 +- ...abetic-obesity-patients-undermining-chronic-use-economics.md | 2 +- ...affordability-not-just-clinical-factors-drive-persistence.md | 2 +- 3 files changed, 3 insertions(+), 3 deletions(-) diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 3f6aac7b5..f9e35f7be 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -50,7 +50,7 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0 ### Additional Evidence (extend) -*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* +*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16* Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index b10ed217f..7be0e49ea 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -55,7 +55,7 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2 ### Additional Evidence (extend) -*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* +*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16* The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful. diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 4ab5daf79..17d557591 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -39,7 +39,7 @@ The source does not provide granular income-stratified discontinuation rates, so ### Additional Evidence (confirm) -*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* +*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16* The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations. -- 2.45.2